Subcutaneous delivery of hyaluronidase may boost effectiveness of cancer immunotherapy

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
The American Journal of Managed Care

FDA Greenlights D-VRd Quadruplet for Newly Diagnosed Multiple Myeloma

D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
Medindia

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

DARZALEX  FASPRO ®   U.S. Prescribing Information. 2 Johnson & Johnson Innovative Medicine. DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet ...
Seeking Alpha

U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor ...

Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile to intravenous Opdivo in the Phase 3 CheckMate-67T trial 1,3 Opdivo and Opdivo ...
Monthly Prescribing Reference

FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab

The product is administered over a period of 3 to 5 minutes into the subcutaneous tissue of the abdomen or thigh by a health care provider. Opdivo Qvantig combines nivolumab, a programmed death ...
WAVY-TV

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when ...

HORSHAM, Pa., Dec. 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT FASPRO™ (amivantamab and ...
Morningstar

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration ...